Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Beam Therapeutics Inc. (BEAM) Balance Sheet

As of 2026-06-30 (10-Q), Beam Therapeutics Inc. (BEAM) reported total assets of $1.4B, total liabilities of $318.9M and shareholders' equity of $1.1B, according to EquiReason's reading of its SEC filings. Cash and equivalents: $219.8M. Long-term debt: $100.3M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

BEAMBeam Therapeutics Inc.Follow BEAM — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
2.5B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
9 Nov, in 16 days
LineFY2020
Dec 20
FY2021
Dec 21
FY2022
Dec 22
FY2023
Dec 23
FY2024
Dec 24
FY2025
Dec 25
Latest
Jun 26
Trend
Cash and equivalents0.160.560.230.440.280.290.22
Short-term investments0.14—0.850.750.570.950.93
Current assets0.311.271.091.210.881.271.18
Total assets0.451.471.341.461.101.481.39
Current liabilities0.100.210.220.210.180.100.08
Long-term debt——————0.10
Total liabilities0.210.650.610.480.370.240.32
Shareholders' equity0.250.830.730.980.731.241.07

USD billions · SEC XBRL

Beam Therapeutics Inc. — questions

How much cash does Beam Therapeutics Inc. have?
$219.8M in cash and cash equivalents as of 2026-06-30.
How much debt does Beam Therapeutics Inc. have?
$100.3M of long-term debt as of 2026-06-30.
What are Beam Therapeutics Inc.'s total assets?
$1.4B as of 2026-06-30.
What is Beam Therapeutics Inc.'s shareholders' equity?
$1.1B as of 2026-06-30.

Every figure on this page comes from Beam Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.